港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

寶濟藥業-B

21.880

-1.160-5.03%

成交量：187.76萬

成交額：4,197.99萬

市值：71.32億

市盈率：-13.89

高：23.300

開：22.800

低：21.800

收：23.040

52周最高：206.000

52周最低：21.800

股本：3.26億

香港流通股本：1.54億

量比：0.67

換手率：1.22%

股息：- -

股息率：- -

每股收益(LYR):-1.576

淨資產收益率：-30.55%

總資產收益率：-10.79%

市淨率：3.87

市盈率(LYR):-13.89

市銷率: 125.23

資料載入中...

總覽公司新聞資訊公告

異動解讀｜寶濟藥業-B盤中下跌5.3%，生物科技板塊系統性走弱延續承壓

寶濟藥業-B公布2026年5月股份變動月報表，股本維持穩定

異動解讀｜寶濟藥業-B盤中下跌5.46%，MSCI納入生效首日遭拋壓疊加板塊走弱

【券商聚焦】中郵證券首予寶濟藥業-B(02659)「增持」評級指公司商業化元年開啓

中郵證券：首予寶濟藥業-B(02659)「增持」評級平台價值逐步兑現

智通财经网

異動解讀｜寶濟藥業-B盤中上漲5.05%，新任董事長落定疊加管線利好

寶濟藥業-B(02659)：劉彥君獲委任為董事長

異動解讀｜寶濟藥業-B盤中下跌5.02%，報25.36港元

異動解讀 | 獲納入MSCI指數及多重利好提振，寶濟藥業-B盤中大漲5.80%

港股異動 | 寶濟藥業-B(02659)最高升逾23% 獲納入MSCI全球指數成分股將於5月29日收市後生效

異動解讀 | 入選夏季路演大會名單，寶濟藥業-B盤中大漲5.18%

異動解讀 | 生物科技板塊整體承壓，寶濟藥業-B盤中大跌5.26%

「2026智通財經夏季路演大會」活動報名中！

智通财经网

寶濟藥業(02659)獲納入MSCI全球指數成分股創新研發實力獲得全球認可

異動解讀 | 控股股東擬增持疊加新品獲批，寶濟藥業-B盤中大漲5.02%

港股異動 | 寶濟藥業-B(02659)早盤升逾7% 注射用KJ103擬納入優先審評

寶濟藥業－Ｂ(02659)股價上升5.022%，現價港幣$28.86

阿斯达克财经

異動解讀 | 寶濟藥業-B盤中大漲5.62%，控股股東增持計劃及新品獲批提振市場信心

異動解讀 | 寶濟藥業-B盤中大漲6.29%，控股股東擬增持及新品獲批提振市場信心

異動解讀 | ...

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02659/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"寶濟藥業-B","latestPrice":21.88,"timestamp":1780387724966,"preClose":23.04,"halted":0,"volume":1877600,"delay":0,"changeRate":-0.05034722222222223,"floatShares":154000000,"shares":325981465,"eps":-1.5757825027234185,"marketStatus":"未開盤","change":-1.16,"latestTime":"06-02 16:08:44","open":22.8,"high":23.3,"low":21.8,"amount":41979880,"amplitude":0.065104,"askPrice":21.88,"askSize":1200,"bidPrice":21.86,"bidSize":3600,"shortable":0,"etf":0,"ttmEps":-1.5560852214393757,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1780450200000},"marketStatusCode":0,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":23.04,"openAndCloseTimeList":[[1780363800000,1780372800000],[1780376400000,1780387200000]],"volumeRatio":0.674881,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":154000000,"roa":"-10.79%","roe":"-30.55%","lyrEps":-1.575783,"volumeRatio":0.674881,"shares":325981465,"dividePrice":0,"high":23.3,"amplitude":0.065104,"preClose":23.04,"low":21.8,"week52Low":21.8,"pbRate":"3.87","psRate":"125.23","week52High":206,"institutionHeld":0,"latestPrice":21.88,"committee":0.5,"eps":-1.5757825027234185,"divideRate":0,"volume":1877600,"delay":0,"ttmEps":-1.5560852214393757,"open":22.8,"prevYearClose":77.55,"prevWeekClose":24.54,"prevMonthClose":24.54,"prevQuarterClose":91.3,"fiveDayClose":24.94,"twentyDayClose":26.02,"sixtyDayClose":154.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-06-01","current":-14.061102,"percent":1,"low":-150.791275,"twenty":-78.760123,"median":-66.033023,"eighty":-50.330094,"high":-16.403454,"avg":-65.878371,"sd":31.445175,"marketCap":7510612953},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-01","current":-16.403454,"twenty":-78.760123,"median":-66.033023,"eighty":-50.330094,"marketCap":7510612953}],"updateTime":1780420589899},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1122877857","title":"異動解讀｜寶濟藥業-B盤中下跌5.3%，生物科技板塊系統性走弱延續承壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1122877857","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122877857?lang=zh_tw&edition=fundamental","pubTime":"2026-06-02 15:52","pubTimestamp":1780386730,"startTime":"0","endTime":"0","summary":"6月2日，宝济药业-B盘中下跌5.3%，报21.82港元/股，成交额3912.25万港元。消息面上，生物科技板块今日延续系统性走弱态势，行业个股普遍承压，其中三生制药跌8.8%、康方生物跌8.28%、科伦博泰生物跌7.35%、信达生物跌2.6%、百济神州跌1.52%，板块整体抛压显著。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长刘彦君落定、中邮证券首予\"增持\"评级、获纳入MSCI全球指数等多重利好催化，但市场信心仍处于修复阶段，在行业系统性回调背景下个股跟随走弱。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127894406","title":"寶濟藥業-B公布2026年5月股份變動月報表，股本維持穩定","url":"https://stock-news.laohu8.com/highlight/detail?id=1127894406","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127894406?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 17:08","pubTimestamp":1780304924,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年6月1日发布2026年5月的证券变动月报表。报告显示，截至5月31日，公司各类已发行股份总体数量保持不变，未进行任何新增发行、购回或注销行为，股本结构稳定。公司本月底法定/注册股本总额为65,196,293元人民币。公告由公司执行董事刘彦君签署，并重申公司遵守香港联交所《上市规则》及其他相关法律规定。根据公告信息显示，公司目前股本维持不变，符合相关监管要求。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117543784","title":"異動解讀｜寶濟藥業-B盤中下跌5.46%，MSCI納入生效首日遭拋壓疊加板塊走弱","url":"https://stock-news.laohu8.com/highlight/detail?id=1117543784","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117543784?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 14:36","pubTimestamp":1780295769,"startTime":"0","endTime":"0","summary":"6月1日，宝济药业-B盘中下跌5.46%，报23.2港元/股，成交额4265.7万港元。消息面上，公司此前获纳入MSCI全球指数成分股，于5月29日收市后正式生效，今日为生效后首个交易日。此外，生物科技板块今日整体承压，百济神州跌3.45%、科伦博泰生物跌6.8%、信达生物跌2.88%，行业系统性走弱加剧个股回调。公司股价自4月底闪崩暴跌65%后持续低位震荡，尽管近期新董事长落定、中邮证券首予\"增持\"评级，但市场信心仍处于修复阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640933019","title":"【券商聚焦】中郵證券首予寶濟藥業-B(02659)「增持」評級 指公司商業化元年開啓","url":"https://stock-news.laohu8.com/highlight/detail?id=2640933019","media":"金吾财讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640933019?lang=zh_tw&edition=fundamental","pubTime":"2026-06-01 13:55","pubTimestamp":1780293315,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中邮证券发布研报指，2025年宝济药业-B 实现总收入4916万元，较2024年的616万元大幅增长，主要得益于4000万元许可收入及首款商业化产品SJ02（晟诺娃）的364万元净收入。年内亏损3.95亿元，亏损同比扩大主要受计提5510万元诉讼拨备等非经营性因素影响。业务层面，首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司进入商业化阶段。核心产品重组人透明质酸酶KJ017于2026年3月31日获批，系国内首款获批产品。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NzE1NDA5NTM3ODk1OQ==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1982646","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639642125","title":"中郵證券：首予寶濟藥業-B(02659)「增持」評級 平台價值逐步兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2639642125","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639642125?lang=zh_tw&edition=fundamental","pubTime":"2026-05-29 14:07","pubTimestamp":1780034864,"startTime":"0","endTime":"0","summary":"公司首款产品长效促卵泡素SJ02于2025年8月获批上市，11月完成首批订单交付，标志公司正式进入商业化阶段。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260529/20260529140811_37744.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260529/20260529140811_37744.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["02659","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1129712989","title":"異動解讀｜寶濟藥業-B盤中上漲5.05%，新任董事長落定疊加管線利好","url":"https://stock-news.laohu8.com/highlight/detail?id=1129712989","media":"行情直击","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129712989?lang=zh_tw&edition=fundamental","pubTime":"2026-05-27 14:50","pubTimestamp":1779864600,"startTime":"0","endTime":"0","summary":"5月27日，宝济药业-B盘中上涨5.05%，报26.24港元/股，成交额8176.22万港元。消息面上，公司于5月26日公告，刘彦君博士获委任为第二届董事会董事长，任期三年。此外，近期公司核心管线注射用KJ103拟纳入优先审评，该产品为全球首创的重组IgG降解酶，适用于高度致敏肾移植患者脱敏治疗。此前公司股价自4月底闪崩暴跌65%后持续低位运行，控股股东已表态拟增持股份，新管理层架构确立叠加研发管线推进，市场情绪有所修复。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638510008","title":"寶濟藥業-B(02659)：劉彥君獲委任為董事長","url":"https://stock-news.laohu8.com/highlight/detail?id=2638510008","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638510008?lang=zh_tw&edition=fundamental","pubTime":"2026-05-26 21:58","pubTimestamp":1779803887,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，刘彦君博士、王征女士及李翠女士获重选为第二届董事会执行董事;林佳陵女士、刁隽桓先生及LiChen先生获重选为第二届董事会非执行董事;及蔡仲曦先生、曾凡一博士、鞠佃文博士及张森泉先生获重选为第二届董事会独立非执行董事。于紧随股东周年大会后举行的第二届董事会第一次会议上，刘彦君博士获委任为第二届董事会董事长，任期自2026年5月26日起至第二届董事会任期届满之日止为期三年。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446266.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111545287","title":"異動解讀｜寶濟藥業-B盤中下跌5.02%，報25.36港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1111545287","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111545287?lang=zh_tw&edition=fundamental","pubTime":"2026-05-21 10:35","pubTimestamp":1779330952,"startTime":"0","endTime":"0","summary":"5月21日，宝济药业-B盘中下跌5.02%，报25.36港元/股，成交额3535.91万港元。宝济药业-B所在的生物科技行业中，板块整体表现偏强，个股中，康方生物涨5.91%，荣昌生物涨4.31%，信达生物涨2.96%，百济神州涨1.93%，三生制药涨0.36%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131609185","title":"異動解讀 | 獲納入MSCI指數及多重利好提振，寶濟藥業-B盤中大漲5.80%","url":"https://stock-news.laohu8.com/highlight/detail?id=1131609185","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131609185?lang=zh_tw&edition=fundamental","pubTime":"2026-05-19 10:27","pubTimestamp":1779157646,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨5.80%，市场表现强劲。消息面上，公司此前宣布成功被纳入MSCI全球小型股指数成分股，相关调整将于5月底收市后正式生效。此次纳入有望为公司股票带来增量被动资金配置，提升市场流动性与国际知名度。此外，公司控股股东刘彦君博士此前宣布的增持计划仍在执行期内，叠加核心产品注射用KJ103拟纳入优先审评等多重利好因素，共同为股价提供了有力支撑。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636028276","title":"港股異動 | 寶濟藥業-B(02659)最高升逾23% 獲納入MSCI全球指數成分股 將於5月29日收市後生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2636028276","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636028276?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 15:52","pubTimestamp":1779090762,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B尾盘最高涨超23%，截至发稿，涨6.22%，报26.66港元，成交额3.61亿港元。消息面上，宝济药业近日宣布，根据MSCI于2026年5月12日公布的指数评审结果，公司成功被纳入MSCI全球小型股指数成分股，相关调整将于2026年5月29日收市后正式生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442861.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0708995401.HKD","02659","LU1691799644.USD","MSCI","LU1804176565.USD","IE00BKPKM429.USD","BK4585","LU0320765059.SGD","LU2095319765.USD","LU0289960550.SGD","BK4112","LU2265009873.SGD","BK4588","VXUS","LU2210150020.SGD","LU0289961442.SGD","LU1267930730.SGD","LU0511384066.AUD","LU0175139822.USD","BK1161","LU0289739343.SGD","LU0109391861.USD","LU0390134368.USD","LU2210149790.SGD","LU0672654240.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147308433","title":"異動解讀 | 入選夏季路演大會名單，寶濟藥業-B盤中大漲5.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=1147308433","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147308433?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 15:18","pubTimestamp":1779088702,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价大幅上涨5.18%，引起了市场的关注。消息面上，智通财经宣布将于5月28日举办“2026智通财经夏季路演大会”，旨在搭建上市公司与投资者之间的沟通桥梁。在已公布的部分路演上市公司名单中，宝济药业-B位列其中。市场分析认为，公司参与此类重要资本市场活动，有助于提升其在投资者群体中的能见度，并可能被视为积极与市场沟通、寻求价值认可的举措，从而提振了股价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164039178","title":"異動解讀 | 生物科技板塊整體承壓，寶濟藥業-B盤中大跌5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164039178","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164039178?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 10:49","pubTimestamp":1779072570,"startTime":"0","endTime":"0","summary":"宝济药业-B(02659)今日盘中股价出现大幅下挫，跌幅达5.26%。消息面上，此次下跌主要受其所在的生物科技行业板块整体表现疲软拖累。板块内多数个股均呈现下跌态势，市场情绪偏向谨慎。同板块中，信达生物、康方生物、科伦博泰生物、百济神州及荣昌生物等个股亦同步走低，显示出板块整体承压的态势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636304327","title":"「2026智通財經夏季路演大會」活動報名中 ！","url":"https://stock-news.laohu8.com/highlight/detail?id=2636304327","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636304327?lang=zh_tw&edition=fundamental","pubTime":"2026-05-18 10:06","pubTimestamp":1779069961,"startTime":"0","endTime":"0","summary":"5月28日，深圳前海。40+港股上市公司集中路演，与机构及高净值投资者面对面交流。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260518/20260518102433_43763.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442727.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1100","00290","01378","02670","02675","00826","08299","00363","06682","02526","00400","BK1155","02685","BK1171","02565","00305","02889","VXUS","01333","02706","06636","02575","02726","LU0314109678.HKD","02142","01021","06090","02729","09696","03858","00650","01396","02228","02659","01300","01907","06051","LU0287142896.SGD","02623","03881","02655","06651","03317","06938","02411","HK0001040143.USD","02652","02650","LU0307460666.USD","01384"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635676392","title":"寶濟藥業(02659)獲納入MSCI全球指數成分股 創新研發實力獲得全球認可","url":"https://stock-news.laohu8.com/highlight/detail?id=2635676392","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635676392?lang=zh_tw&edition=fundamental","pubTime":"2026-05-14 09:54","pubTimestamp":1778723663,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，2026年5月14日，宝济药业宣布，根据MSCI于2026年5月12日公布的指数评审结果，公司成功被纳入MSCI全球小型股指数成分股，相关调整将于2026年5月29日收市后正式生效。此次被纳入该指数，标志着宝济药业在全球资本市场的知名度和影响力进一步提升，将有助于公司股票获得更广泛的国际投资者关注，带来增量被动资金的潜在配置，并进一步提升股份的市场流动性、交易活跃度及国际知名度。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1804176565.USD","LU0320765059.SGD","IE00BKPKM429.USD","BK4588","LU0289739343.SGD","LU0708995401.HKD","LU0289961442.SGD","BK4112","LU0390134368.USD","LU2210149790.SGD","LU0672654240.SGD","LU0511384066.AUD","LU2095319765.USD","LU2210150020.SGD","LU1691799644.USD","LU0175139822.USD","LU0289960550.SGD","02659","BK1161","LU1267930730.SGD","BK4585","LU0109391861.USD","LU2265009873.SGD","MSCI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103794009","title":"異動解讀 | 控股股東擬增持疊加新品獲批，寶濟藥業-B盤中大漲5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1103794009","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103794009?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 10:07","pubTimestamp":1778638055,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨5.02%，引起了市场的广泛关注。消息面上，此次股价上涨主要受到两大利好因素的推动。首先，公司董事会主席兼控股股东刘彦君博士宣布，计划在三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举向市场释放了控股股东对公司长期价值坚定认可的积极信号。控股股东的增持意愿与核心新产品的成功获批形成合力，共同提振了市场信心，推动了股价的强势表现。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635220997","title":"港股異動 | 寶濟藥業-B(02659)早盤升逾7% 注射用KJ103擬納入優先審評","url":"https://stock-news.laohu8.com/highlight/detail?id=2635220997","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635220997?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 10:07","pubTimestamp":1778638033,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宝济药业-B(02659)早盘涨超7%，截至发稿，涨6.99%，报29.4港元，成交额8606.39万港元。消息面上，5月12日，CDE官网显示，宝济药业注射用KJ103拟纳入优先审评，适用于高度致敏的肾移植患者进行脱敏治疗，有效清除预存HLA抗体预防超急性排斥反应。据介绍，KJ103是一款全球首创、低免疫原性的重组免疫球蛋白G(IgG)降解酶，用于治疗由病理性IgG抗体介导的多种免疫性疾病。该产品通过特异性切割并降解血液循环中的病理性IgG抗体，抑制免疫应答激活，为抗体介导的自身免疫性疾病提供了靶向、快速的治疗新选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441018.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659","BK4588","BK4585","BK1161","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635204602","title":"寶濟藥業－Ｂ(02659)股價上升5.022%，現價港幣$28.86","url":"https://stock-news.laohu8.com/highlight/detail?id=2635204602","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635204602?lang=zh_tw&edition=fundamental","pubTime":"2026-05-13 10:04","pubTimestamp":1778637840,"startTime":"0","endTime":"0","summary":"[上升股]宝济药业－Ｂ(02659) 股价在上午10:04比前收市价上升5.022%，现股价为港币$28.86。至目前为止，今日最高价为$28.86，而最低价为$27.4。总成交量为221.672万股，总成交金额为港币$6.253千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152549604_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605131148/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2605131148/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147725778","title":"異動解讀 | 寶濟藥業-B盤中大漲5.62%，控股股東增持計劃及新品獲批提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1147725778","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1147725778?lang=zh_tw&edition=fundamental","pubTime":"2026-05-11 09:49","pubTimestamp":1778464170,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨5.62%，引起了投资者的广泛关注。消息面上，公司董事会主席兼控股股东集团成员刘彦君博士此前宣布，拟于三个月内通过公开市场增持公司股份，最高不超过3889.39万股H股，此举持续向市场释放了对公司长期价值的认可信号。同时，公司的注射用人玻璃酸酶已获国家药监局批准上市，为产品管线再添商业化品种，增强了未来的盈利预期。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118222667","title":"異動解讀 | 寶濟藥業-B盤中大漲6.29%，控股股東擬增持及新品獲批提振市場信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1118222667","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118222667?lang=zh_tw&edition=fundamental","pubTime":"2026-05-08 10:05","pubTimestamp":1778205923,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅上涨6.29%，引起市场关注。消息面上，此次股价上涨主要受到两方面积极因素的推动。首先，公司董事会主席兼控股股东集团成员刘彦君博士基于对公司前景及增长潜力的信心，计划在未来三个月内通过公开市场交易增持公司股份，此举向市场释放了内部人士对公司长期价值的认可信号。其次，公司产品管线传来利好，其注射用人玻璃酸酶此前已获得国家药品监督管理局批准上市，为公司再添一款商业化产品，增强了其在医药领域的竞争力。控股股东的增持计划与核心新产品的成功获批相结合，共同构成了推动本次股价走强的关键驱动力，有效提振了投资者的信心。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101188590","title":"異動解讀 | ...","url":"https://stock-news.laohu8.com/highlight/detail?id=1101188590","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101188590?lang=zh_tw&edition=fundamental","pubTime":"2026-05-07 10:54","pubTimestamp":1778122483,"startTime":"0","endTime":"0","summary":"...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":117,"code":"91000000","status":"200"}]}}